Rhenman & Partners Asset Management Trims Neurocrine Biosciences Stake

Hedge fund reduces holdings in biotech company by 23% in Q3

Published on Mar. 8, 2026

Got story updates? Submit your updates here. ›

Rhenman & Partners Asset Management AB, a Swedish investment firm, reduced its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 23.1% in the third quarter, according to a recent SEC filing. The firm now owns 114,717 shares of the company's stock, making it Neurocrine Biosciences' 21st largest institutional investor.

Why it matters

Neurocrine Biosciences is a prominent biopharmaceutical company focused on developing treatments for neurological and psychiatric disorders. The reduction in Rhenman & Partners' stake could signal a shift in investor sentiment towards the company or the broader biotech sector.

The details

According to the 13F filing, Rhenman & Partners sold 34,500 shares of Neurocrine Biosciences during the third quarter. The firm now owns approximately 0.12% of the company's outstanding shares, valued at $16.1 million as of the most recent SEC reporting period.

  • Rhenman & Partners reduced its Neurocrine Biosciences holdings in the 3rd quarter of 2026.

The players

Rhenman & Partners Asset Management AB

A Swedish investment firm that manages a portfolio of biotech and healthcare stocks.

Neurocrine Biosciences, Inc.

A biopharmaceutical company focused on developing treatments for neurological and psychiatric disorders, including tardive dyskinesia.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Rhenman & Partners' Neurocrine Biosciences stake could signal broader uncertainty in the biotech sector, though the company's core business and pipeline remain intact. Investors will likely monitor Neurocrine's future performance and any changes in institutional ownership.